Australia's most trusted
source of pharma news
Thursday, 24 April 2025
Posted 22 April 2025 PM
Bitter tit-for-tat accusations between PBAC and industry over who's to blame for Australia's appalling record on medicines access has prompted Rare Cancers Australia to call for a truce.
RCA CEO Christine Cockburn has called time out on the slinging match which reared its head again last week after PBAC pointed an accusatory finger at industry over several issues, including so-called "submission churn".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.